

WilmerHale Reps Apellis Pharmaceuticals in Initial Public Offering

NOVEMBER 14, 2017

On November 13, 2017, Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced the closing of its initial public offering of 10,714,000 shares of common stock at a public offering price of \$14.00 per share. The total gross proceeds to Apellis were approximately \$150.0 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares were sold by Apellis. In addition, Apellis granted the underwriters a 30-day option to purchase up to 1,607,100 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The shares commenced trading on the NASDAQ Global Select Market under the ticker symbol “APLS” on Thursday, November 9, 2017.

WilmerHale represented Apellis in this transaction with a deal team that included [Stuart Falber](#), [Chris Barnstable-Brown](#), [Craig Hilts](#), [Mhairi Immermann](#) and [Alicia Lee](#).

[View the full press release.](#)